Coverage of research presented by Strategic Alliance Partners: OneOncology, Florida Cancer Specialists & Research Institute, and The US Oncology Network.
Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.
/PRNewswire/ At the 2023 ASCO annual meeting, investigators from OneOncology s clinical team will present Oral Abstracts using real-world data to evidence.